

CURRICULUM VITAE

Stephen W. Behrman, M.D., F.A.C.S.

Department of Surgery
Baptist Surgical Specialists
80 Humphries Center, Suite 201
Memphis, TN 38120
901-226-5957; Fax: 901-226-5940
stephenbehrmanmd@gmail.com

Birthplace: Brockton, Massachusetts

Education:

Undergraduate:

Boston University, Boston, Massachusetts; August, 1978 – May, 1982
Bachelor of Arts, Magna Cum Laude

Medical School:

Boston University Medical School, Boston, Massachusetts; August, 1983 – June, 1987
Doctor of Medicine

Residency/Internship:

University of Tennessee, Memphis, Tennessee; July, 1987 – June, 1989
General Surgery Residency

Research Fellowship:

University of Tennessee, Memphis, Tennessee; July, 1989 – June 1990
Departments of Surgery and Physiology

Residency:

University of Tennessee, Memphis, Tennessee; July, 1990 – June 1993
General Surgery Residency

Surgical Fellowship:

Grant Medical Center and The Ohio State University, Columbus, Ohio; July, 1993 – June, 1994
Gastrointestinal Surgery

Leadership:

MEDI Leadership – 2017-8.
Mentor/Coach – Mr. Eric P. Norwood, FACHE, PCC
Baptist Executive Leadership Institute/University of Memphis – 2018-9.

Honors/Awards:

James W. Pate, MD Award, Harwell Wilson Surgical Society, Memphis, Tennessee "Effect of Hypertonic Saline/Dextran on blood flow distribution after shock", May 1990

James W. Pate, MD Award, Harwell Wilson Surgical Society, Memphis, Tennessee "Effect of growth hormone on nutritional markers in Enterally fed immobilized trauma patients" May 1991

Presenter, American College of Surgeons Committees on Trauma, Region IV Residents' Papers Competition, Atlanta, Georgia (1990), Birmingham, Alabama, (1991) November 1990, 1991

State Finalist, Tennessee Committee on Trauma, Residents' Paper Competition, Nashville, Tennessee, November 1988, 1990, 1991

Top Surgeon, Memphis Magazine, 2008-21

Surgical Faculty Teaching Award, University of Tennessee Health Science Center Department of Surgery 2016

Military Service:

1988 - 1991 Lieutenant, Medical Corps, Naval Reserve

1991 - 1999 Lieutenant Commander, Medical Corps, Naval Reserve

1999 - 2005 Commander, Medical Corps, Naval Reserve

2003 - March – May Active Duty, Operation Iraqi Freedom and Noble Eagle. Stationed at: National Naval Medical Center, Bethesda, MD and Naval Hospital Guantanamo Bay, Cuba

2005 Honorable Discharge, United States Navy

Board Certification:

American Board of Surgery, September, 1994
Recertified, October, 2001
Recertified, November, 2012

Medical Licensure:

New Hampshire, July 1994 (expired)
California #G81941, September 27, 1995 (expired)
Tennessee #MD0000029455, June 25, 1997 (active)

Society Memberships:

American College of Surgeons
American Hepato-Pancreato-Biliary Association
Pancreas Club
Society for Surgery of the Alimentary Tract

Ad Hoc Manuscript Review:

Archives of Surgery
American Surgeon
Annals of Surgical Oncology
Annals of Surgery
Hepatobiliary & Pancreatic Diseases
Infection
Journal of the Pancreas
Journal of Surgical Oncology
Langenbecks Archives of Surgery
Pancreatology
Surgery
The International Journal of Hepatobiliary and Pancreatic Diseases
Journal of the American College of Surgeons
Journal of Gastrointestinal Surgery
HPB Journal
Journal of Surgical Research
Surgical Oncology

Editorial Board:

Journal of Gastrointestinal Surgery – 2019- present.

Professional Experience:

1994 – 1995 Private Practice in Surgery, Catholic Medical Center, Manchester, New Hampshire

University Appointments:

1995 – 1997	Assistant Clinical Professor of Surgery University of San Francisco/Fresno-Central San Joaquin Valley Medical Education Program
1997 - 2000	Assistant Professor of Surgery University of Tennessee, Memphis
2000 - 2012	Associate Professor of Surgery (Tenured July 2003) University of Tennessee Health Science Center, Memphis

2013 – present	Professor of Surgery University of Tennessee Health Science Center, Memphis
2019 – present	Staff Surgeon, Baptist Medical Group/ Baptist Cancer Center
2021 – present	Program Chair, General Surgery Residency, Baptist Memorial Hospital- Memphis

Hospital Appointments:

Baptist Memorial Hospital, Memphis, Tennessee, 1997 - Present (Active)

Methodist Hospital, Memphis, Tennessee; 1997 - Present (Active)

Veteran’s Administration Hospital, Memphis, Tennessee; 1997 - 2019

Invited Lectures:

October 26 – 30, 2014	“Observation of IPMN of the Pancreas: Why, When, and How” American College of Surgeons Clinical Congress, San Francisco, CA
-----------------------	--------------------------------------------------------------------------------------------------------------------------------

September 20, 2014	“Partial vs Total Pancreatectomy for IPMN in the Young Patient” at The Inaugural Raza A. Dilawari Multidisciplinary Cancer Symposium, Memphis, TN
--------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------

March 28, 2014	American Association of Critical Care Nursing Memphis Chapter St. Francis Hospital, Memphis “Pathophysiology and Perioperative Care of Esophageal Cancer”
----------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------

February 20, 2013	Surgery Grand Rounds University of Tennessee, Chattanooga Chattanooga, TN “Pancreatic Cancer-Toward Optimizing Outcome”
-------------------	----------------------------------------------------------------------------------------------------------------------------------

March 6-10, 2012	American Hepato-Pancreatico-Biliary Association Miami, Florida “Technical toolbox – Whipple procedure Should I Place a J-tube”
------------------	-----------------------------------------------------------------------------------------------------------------------------------------

November 1, 2008	Gastrointestinal Cancer: The Big Picture Prevention, Detection and Treatment Baptist Centers for Cancer Care University of Memphis “Laparoscopic versus Open Colectomy for Cancer”
------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

January 9, 2008	Surgery Grand Rounds University of Tennessee, Chattanooga Chattanooga, TN “Uncommon Pancreatic Neoplasms”
June 8-9, 2001	Update in General Surgery University of Tennessee, Memphis "Current Surgical Issues in Pancreatic Carcinoma" "Current Surgical Issues in Inflammatory Bowel Disease”
July 11, 2000	Practice Update in Medicine for the Primary Care Physicians Charleston, South Carolina "Advanced Laparoscopic Procedures"
June 10, 1999	Update in General Surgery University of Tennessee, Memphis "Management of Malignant Small Bowel Fistulae and Obstruction"
June 4, 1998	Update in General Surgery University of Tennessee, Memphis “ <i>Helicobacter pylori</i> and Gastroduodenal Disease: Cure or Curiosity?”
June 5, 1997	Update in General Surgery University of Tennessee, Memphis “Uncommon Pancreatic Malignancies”

Grant Support:

Baptist Foundation Innovation Grant (Stephen W. Behrman – PI) 1/1/2020-12/31/2022

Outcomes following Neoadjuvant Chemoradiation and Assessment of Germline and Somatic Alterations in Ampullary and Duodenal Adenocarcinoma

To assess genetic alterations and actionable mutations that may occur in these rare tumors that may be amendable to targeted therapies.

Total Amount: \$50,000

1R01CA204552-01 NIH/NCI (Chauhan-PI, Behrman-Collaborator) 07/11/2016-05/31/2021

MUC13 Mucin in Colorectal Cancer Health Disparity

NIH/NCI

To investigate role of MUC13 mucin in colorectal cancer health disparity and evaluate its diagnostic/prognostic potential.

Total Amount: \$1.7 million

1R01CA210192-01 NIH/NCI (Chauhan-PI, Behrman-Collaborator) 06/24/2016 – 05/31/2021

Targeted Nanotherapy for Pancreatic Cancer

To evaluate efficacy of a targeted nanoparticle formulation for pancreatic cancer treatment alone and combination with Gemcitabine.

Total Amount: \$1.7 million

1R01CA206069-01A1 NIH/NCI (Chauhan-PI, Behrman-Collaborator) 06/24/2016 – 05/31/2021

Development of a Targeted Nanotechnology platform for Pancreatic Cancer

To develop a curcumin loaded magnetic nanoparticle formulation for altered tumor microenvironment and chemo-sensitization of pancreatic cancer.

Total Amount: \$1.7 million

UT 14-0558 Kosten Foundation, Memphis (Chauhan-PI, Behrman-Collaborator)) 03/01/14-02/28/17

Pancreatic Cancer Research Support Funds

Total Amount: \$.2 million

Herb Kosten Pancreatic Cancer Endowment Fund at the University of Tennessee

2011 – 2019

“The interaction of microRNA-145, MUC13 and the growth and invasion of pancreatic adenocarcinoma”

Co-Investigators: Stephen W. Behrman, MD

Subhash Chauhan, Ph.D.

Total Amount: \$1,000,000

Baptist Memorial Health Care Foundation

2012—2016

“Randomized Prospective Multicenter Trial of Pancreas Resection with and Without Routine Intraoperative Drainage”

Investigator: William E. Fisher, MD

Co-Investigator: Stephen W. Behrman, MD

Total Amount: \$60,000

Regional, National, and International Committees:

Pancreatic Carcinoma Committee - National Comprehensive Cancer Network 2007-present

Committee Lead – Development of Ampullary Cancer Guidelines - 2021

Program Committee – American Hepato-Pancreato-Biliary Association, 2011-12, 2017-present

Program Committee – International Hepato-Pancreato-Biliary Association, 2011-12, 2020

Program Committee – Society for Surgery of the Alimentary Tract, 2017-present

Clinical Trials Committee – Society for Surgery of the Alimentary Tract, 2020-2021

American College of Surgeons National Surgical Quality Improvement

Program/Tennessee State Quality Collaborative – 2009-present

Leadership Committee- 2017-present.

Chair – January 2019 - 21.

Southwest Oncology Group – 2017-present
Surgery Committee
Gastrointestinal Committee
Surgery Committee liaison to the Gastrointestinal Committee – 2020-present
National Cancer Institute Gastrointestinal Steering Committee, Pancreas Task Force
2017-present

National Educational Leadership:

Associate Examiner, American Board of Surgery, 2017
American Board of Surgery, Operative Decision Making, Continuing Medical Education
– Pancreas Panel, 2017 - present

Local Committees and Offices Held:

Medical Director, Surgical Services, Baptist Memorial Hospital, 2012-present
Chairman, Department of Surgery, Baptist Memorial Hospital, 2012 –present
Physician Champion, American College of Surgeons National Surgical
Quality Improvement Program, Baptist Memorial Hospital, 2011-present
Vice-Chair, Medical Executive Committee, Baptist Memorial Hospital, 2011
President, Medical Staff, Baptist Memorial Hospital, January 2010-2012
Vice President, Medical Staff, Baptist Memorial Hospital, January, 2008 – 2010
Medical Staff Leadership Committee, Baptist Memorial Hospital, 2009-present
Graduate Medical Education Committee, Baptist Memorial Hospital, 2008-present
Chair – General Surgery Service Line, 2017-present
Chair - Surgical Services Oversight Committee, 2016-present

Institutional Leadership:

Chair, Surgical Services Oversight Committee, Baptist Memorial Hospital 2015 – present
Chair, General Surgery Service Line, Baptist Memorial Hospital 2017-20
Chief, Gastrointestinal Oncology, Baptist Memorial Hospital 2016 – present
Co-Director, GI Multi-disciplinary Program, Baptist Cancer Center 2016- present
Director, Incidental Abdominal Nodule Program, Baptist Cancer Center 2017-present

University Committees:

Ph.D advisory committee:
Neeraj Chauhan – Department of Pharmaceutical Sciences, UTHSC - 2019
Aditya Ganju – Department of Pharmaceutical Sciences, UTHSC - 2019
Sanai Setua – Department of Pharmaceutical Sciences, UTHSC - 2020
Kyle Doxtater – Department of Pharmaceutical Sciences, UTHSC
Andrew E. Massey – Department of Pharmaceutical Sciences, UTHSC - 2020

Community Leadership:

Medical Director, Kosten Pancreatic Cancer Foundation

Departmental Responsibilities:

Surgical Education Committee

Herb Kosten Distinguished Lectureship

2007 – Richard C. Karl, M.D.

Richard G. Connor Professor and Chairman

Department of Surgery

University of South Florida College of Medicine

“Cystic Neoplasms of the Pancreas – When to Intervene”

2008 – David B. Adams, M.D.

Professor and Head

Section of Gastrointestinal and Laparoscopic Surgery

General and Gastrointestinal Surgery

Medical University of South Carolina

“Making Pancreatoduodenectomy Safe”

2009 - John P. Hoffman, M.D., F.A.C.S.

Chief, Pancreaticobiliary Service

Surgical Oncology

Fox Chase Cancer Center

Philadelphia, Pennsylvania

“Proper Staging, Resection and Processing of Pancreatic Adenocarcinoma”

2010 - Vic Velanovich, M.D.

Head, Division of General Surgery

Henry Ford Hospital

Detroit, Michigan

“Quality of Life of Pancreatic Cancer and Resection”

2011 – Thomas J. Howard, M.D.
Willis D. Gatch Professor of Surgery
Indiana University
Indianapolis, IN
“Elephants in the Room: Obstacles to Cure in Pancreas Cancer”

2014 – Christopher Wolfgang, M.D.
Associate Professor of Surgery
Johns Hopkins University School of Medicine
“Current Concepts in the Management of Pancreatic Cancer”

2016 – Russell G. Postier, M.D.
Professor of Surgery
University of Oklahoma Health Science Center
“The Challenge of Pancreatic Cancer”

2017 – Charles M. Vollmer, M.D.
Professor of Surgery
University of Pennsylvania, Perelman School of Medicine
“An Odyssey with Pancreatic Fistula”

2018 – David A. Kooby, M.D.
Professor of Surgery
Emory University School of Medicine
“Minimally invasive pancreatic resection: a journey of patient care, research and international collaboration”

Volunteer: Crohn's and Colitis Foundation, Memphis, Tennessee
Herb Kosten Pancreatic Cancer Support Group

Publications:

1. **Behrman SW**, Fabian TC, Kudsk KA, Taylor JC. Early fixation of femur fractures; an analysis based on injury severity. *J Trauma* 1990; 30(7): 7792-7798.
2. **Behrman SW**, Fabian TC, Kudsk KA, Proctor KG. Mesenteric blood flow redistribution after resuscitation of hemorrhagic shock with 7.5% Hypertonic Saline/6% Dextran 70. *J Trauma* 1991;31(5):589 – 599.
3. **Behrman, SW**, Waojtysiak S, Brown RO, Vehe KL, Fabian TC, Kudsk KA. The Effect of growth hormone on nutritional markers in enterally fed immobilized trauma patients. *Surgical Forum* 1990: 20-22.
4. **Behrman SW**, Fabian TC, Kudsk KA, Proctor KG. Microcirculatory flow changes after initial resuscitation of hemorrhagic shock with 7.5% hypertonic Saline/6% Dextran 70. *J Trauma* 1991;31(5):589-600.
5. **Behrman SW**, Waojtysiak S, Brown RO, Vehe KL, Fabian TC, Kudsk KA. The effect of growth hormone on nutritional markers in enterally fed immobilized trauma patients. *J Parenter Enteral Nutr* 1995;19(1): 41-46.

6. **Behrman SW**, Melvin WS, Ellison EC. Pancreatic pseudocysts following acute pancreatitis. *Am Surg* 1996;172(9):228-231.
7. **Behrman SW**, Melvin WS, Babb ME, Johnson JJ, Ellison EC. Laparoscopic cholecystectomy in the geriatric population. *Am Surg* 1996;62(5):386-390.
8. **Behrman SW**, Bertken KA, Stefanacci HA, Parks SN. Breakdown of intestinal repair after laparotomy for trauma: incidence, risk factors, and strategies for prevention. *J Trauma* 1998;45(2):227-233.
9. Gibson JB, **Behrman SW**, Fabian TC, Britt LG. Gastric outlet obstruction resulting from peptic ulcer disease requiring surgical intervention is infrequently associated with *Helicobacter pylori*: Preliminary guidelines for patient management. *J Am Coll Surg* 2000;191(1):32 – 37.
10. Callicutt LS, **Behrman SW**. The incidence of *Helicobacter pylori* in operatively managed acute non-variceal upper gastrointestinal bleeding. *J Gastrointest Surg* 2001;5(6):614-619.
11. Kelly ME, **Behrman SW**: The safety and efficacy of prosthetic hernia repair in clean-contaminated and contaminated wounds. *Am Surg* 2002;68(6):524-529.
12. **Behrman SW**. Invited Critique. Selection of pancreaticojejunostomy techniques according to pancreatic texture and duct size. *Arch Surg* 2002;137(9):1048.
13. **Behrman SW**, Rush B, Dilawari RA. A modern analysis of morbidity following pancreatic resection. *Am Surg* 2004;70(8):675-683.
14. **Behrman SW**. Management of complicated peptic ulcer disease. Collective Review. *Arch Surg* 2005; 140(2):201-208.
15. **Behrman SW**, Mulloy M. Total pancreatectomy for chronic pancreatitis: indications, outcomes and recommendations. *Am J Surg* 2006;72(4):297-302.
16. Logue AJ, **Behrman SW**. Recurrent metachronous metastatic multifocal renal cell carcinoma to the pancreas. *Am Surg* 2007;73(4):407-409.
17. **Behrman SW**, Moinuddin SM, Gravenor DS. Clinical and radiologic resolution of IgG4 normal, nonoperatively diagnosed lymphoplasmacytic sclerosing pancreatitis after initiation of steroid therapy. *J Gastrointest Surg* 2007;11(9): 1194-1196.
18. **Behrman SW**, Zarzaur BL. Intra-abdominal sepsis following pancreatic resection: incidence, risk factors, diagnosis, microbiology, management and outcome. *Am J Surg* 2008;74(7):572-579.
19. Tempero MA, Arnoletti JP, **Behrman SW**, Ben-Josef E, Benson AB 3rd, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW 2nd, Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting W, Willett C, Wolff RA. NCCN Pancreatic Adenocarcinoma. *J Natl Compr Canc Netw* 2010 Sept;8(9):972-1017.

20. **Behrman SW**, Bahr MH, Dickson PV, Zarzaur, BL. The microbiology of secondary and postoperative pancreatic infections: Implications for antimicrobial therapy. *Arch Surg* 2011;146(5):613-619.
21. Vollmer CM Jr, Sanchez N, Gondek S, McAuliffe J, Kent TS, Christein JD, Callery MP; Pancreatic Surgery Mortality Study Group. *J Gastrointest Surg.* 2012 Jan;16(1):89-102.
22. Duszak R, **Behrman SW**. National Trends in Percutaneous Cholecystostomy Between 1994 and 2009: Perspectives from Medicare provider Claims. *J Am Coll Radiol* 2012;9:474-479.
23. Tempero MA, Arnoletti JP, **Behrman SW**, Ben-Josef E, Benson AB 3rd, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malaf MP, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA.: Pancreatic Adenocarcinoma, Version 2.2012: Featured Updates to the NCCN Guidelines. *J Natl Compr Canc Netw* 2012;10(6):703-713.
24. Saurabh S, Chitkara D, Mehrazin R, **Behrman SW**, Wake RW, Mahato RI. Chemoresistance in Prostate Cancer Cells Is Regulated by miRNAs and Hedgehog Pathway.(2012) *PLoS One* 7(6):e40021.doi:10.1371/journal.pone.0040021. June 29, 2012.
25. Singh S, Chitkara D, Kumar V, **Behrman SW**, Mahato RI. miRNA profiling in pancreatic cancer and restoration of chemosensitivity *Cancer Lett* 2013;334(2):211-220.
26. Chitkara D, Singh S, Kumar V, Danquah M, **Behrman SW**, Kumar N, Mahato RI. Micellar Delivery of Cyclophamide and Gefitinib for Treating Pancreatic Cancer. *Mol Pharm* 2012;9(8):2350-2357.
27. Denbo JW, Orr WS, Zarzaur BL, **Behrman SW**. Toward defining the grade C pancreatic fistula following pancreaticoduodenectomy: incidence, risk factors, management and outcome. *HPB (Oxford)* 2012;14(9):589-593.
28. Paulus EM, Zarzaur BL, **Behrman SW**. Routine peritoneal drainage of the operative bed following elective distal pancreatectomy – Is it necessary? *Am J Surg* 2012;204(4):422-427.
29. Danquah M, Singh S, **Behrman SW** [same as 25], Mahato RI. Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. *Expert Opin Drug Deliv* 2012;9(12):1443 – 1447.
30. Miller BC, Christein JD, **Behrman SW**, Callery MP, Drebin JA, Kent TS, Pratt WB, Lewis RS Jr, Vollmer CM Jr. Assessing the impact of a fistula after a pancreaticoduodenectomy using the postoperative morbidity index. *HPB (Oxford)* 2013;15(10):781-788.
31. Miller BC, Christein JD, **Behrman SW**, Drebin JA, Pratt WB, Callery MP, Vollmer CM Jr. A multi-institutional external validation of the fistula risk score for pancreatoduodenectomy. *J Gastrointest Surg* 2014;18(1):172-180.
32. Cullinan DR, **Behrman SW**. Multi-visceral resection including the pancreas for locally advanced extra-pancreatic carcinoma - a critical appraisal. *Hepatobiliary Pancreat Dis Int* 2014;13(2):189-202.

33. Parikh JG, **Behrman S**, Narra S, Luda M, Callihan, T, Dress MA. Extraosseous plasmacytoma of the stomach. *Gastrointes Endosc* 2014; 80(2):341 – 342.
34. Van Buren G 2nd, Bloomston M, Hughes SJ, Winter J, **Behrman, SW**, Zyromski NJ, Vollmer C, Velanovich V, Riall T, Muscarella P, Trevino J, Nakeeb A, Schmidt CM, Behrns K, Ellison EC, Barakat O, Perry KA, Drebin J, House M, Abdel-Misih S, Silberfein EJ, Goldin S, Brown K, Mohammed S, Hodges SE, McElhany A, Issazadeh M, Jo E, Mo Q, Fisher WE. A randomized prospective multicenter trial of pancreaticoduodenectomy with and without routine intraperitoneal drainage. *Ann Surg* 2014;259(4):605-12.
35. Mittal A, Chitkara D, **Behrman SW**, Mahato RI. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. *Biomaterials* 2014;35(25): 7077–7087.
36. Ganju A, Yallapu MM, Khan S, **Behrman SW**, Chauhan SC, Jaggi M. Nanoways to overcome docetaxel resistance in prostate cancer. *Drug Resist Update* 2014;17(1-2):13 – 23.
37. Lee MK 4th, Lewis RS, Strasberg SM, Hall BL, Allendorf JD, Beane JD, **Behrman SW**, Callery MP, Christein JD, Drebin JA, Epelboym I, He J, Pitt HA, Winslow E, Wolfgang C, Vollmer CM Jr. Defining the post-operative morbidity index for distal pancreatectomy. *HPB (Oxford)* 2014;16(10):915-923.
38. McMillan MT, Christein JD, Callery MP, **Behrman SW**, Drebin JA, Kent TS, Miller BC, Lewis RS Jr, Vollmer CM Jr. Prophylactic octreotide for pancreatoduodenectomy: more harm than good? *HPB (Oxford)* 2014; 16(10):954 – 962.
39. Tempero MA, Malafa MP, **Behrman SW**, Benson AB 3rd, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. *J Natl Compr Canc Netw* 2014; 12(8):1083 – 1093.
40. **Behrman SW**, Zarzaur BL, Parmar A, Riall TS, Hall BL, Pitt HA. Routine drainage of the operative bed following elective distal pancreatectomy does not reduce the occurrence of complications. *J Gastrointest Surg* 2014;19(1):72-79.
41. Khan S, Ebeling MC, Zaman MS, Sikander M, Yallapu MM, Chauhan N, Yacoubian AM, **Behrman SW** s, Zafar N, Kumar D, Tompson PA, Jaggi M, Chauhan SC. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. *Oncotarget* 2014; 5(17):7599 – 7609.
42. McMillan MT, Fisher WE, Van Buren G 2nd, McElhany A, Bloomston M, Hughes SJ, Winter J, **Behrman SW**, Zyromski NJ, Velanovich V, Brown K, Morgan KA, Vollmer C. The value of drains as a fistula mitigation strategy for pancreatoduodenectomy: something for everyone? Results of a randomized prospective multi-institutional study. *J Gastrointest Surg.* 2015 Jan;19(1):21-30; discussion 30-1.
43. Vollmer CM Jr, Lewis RS, Hall BL, Allendorf JD, Beane JD, **Behrman SW**, Callery MP, Christein JD, Drebin JA, Epelboym I, He J, Pitt HA, Winslow E, Wolfgang C, Strasberg SM. Establishing a quantitative

benchmark for morbidity in pancreatoduodenectomy using ACS-NSQIP, the Accordion Severity Grading System, and the Postoperative Morbidity Index. *Ann Surg* 2015; 261(3):527 – 536.

44. Datta J, Lewis RS Jr., Strasberg SM, Hall BL, Allendorf JD, Beane JD, **Behrman SW**, Callery MP, Christein JD, Drebin JA, Epelboym I, He J, Pitt HA, Winslow E, Wolfgang C, Lee MK 4th, Vollmer CM Jr. Quantifying the burden of complications following total pancreatectomy using the postoperative morbidity index; a multi-institutional perspective. *J Gastrointest Surg* 2015Mar;19(3):506-15.
45. Khan S, Chauhan N, Yallapu MM, Ebeling MC, Balakrishna S, Ellis RT, Thompson PA, Balabathula P, **Behrman SW**, Zafar N, Singh MM, Halaweish FT, Jaggi M, Chauhan SC. Nanoparticle formulation of ormeloxifene for pancreatic cancer. *Biomaterials* 2015; 53:731 – 743.
46. Khan S, Ebeling MC, Chauhan N, Thompson PA, Gara RK, Ganju A, Yallapu MM, **Behrman SW**, Zhao H, Zafar N, Singh MM, Jaggi M, Chauhan SC. Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. *Cancer Res* 2015 Jun 1;75(11):2292-304.
47. Khan S, Chauhan N, Yallapu MM, Ebeling MC, Balalrishna S, Ellis RT, Thompson PA, Balabathula P, **Behrman SW**, Zafar N, Singh MM, Halaweish FT, Jaggi M, Chauhan SC. Nanoparticle formulation of ormeloxifene for pancreatic cancer. *Biomaterials* 2015;53:731-43.
48. Valero V 3rd, Grimm JC, Kilic A, Lewis RL, Tosoian JJ, He J, Griffin JF, Cameron JL, Weiss MJ, Vollmer CM Jr, Wolfgang CL; Pancreas Readmission Assessment Group Study. A novel risk scoring system reliably predicts readmission after pancreatectomy. *J AM Coll Surg* 2015; 220:701 – 713.
49. McMillan, MT, Vollmer CM, Asbun HJ, Ball CG, Bassi C, Beane JD, Berger AC, Bloomston M, Callery MP, Christein JD, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, Haverick E, House MG, Hughes SJ, Kent TS, Kunstman JW, Malleo G, McElhany AL, Salem RR, Soares K, Sprys MH, Valero V 3rd, Watkins AA, Wolfgang CL, **Behrman SW**. The characterization and prediction of ISGPF grade C fistulas following pancreatoduodenectomy. *J Gastrointest Surg.* 2016 Feb;20(2):262-76.
50. Marino KA, Hendrick L, **Behrman SW**. Surgical management of complicated pancreatic pseudocysts following acute pancreatitis. *Am J Surg* 2016; 211(1): 109 – 114.
51. Gupta RK, Xie BH, Patton KT, Lisovsky M, Burks E, **Behrman SW**, Klimstra D, Deshpande V. Follicular pancreatitis: a distinct form of chronic pancreatitis – an additional mimic of pancreatic neoplasms. *Hum Pathol* 2016 Feb;48:154-62.
52. McMillan MT, Christein JD, Callery MP, **Behrman SW**, Drebin JA, Hollis RH, Kent TS, Miller BC, Sprys MH, Watkins AA, Strasberg SM, Vollmer CM Jr. Comparing the burden of pancreatic fistulas after pancreatoduodenectomy and distal pancreatectomy. *Surgery.* 2016 Apr;159(4):1013-22.
53. McMillan MT, Soi S, Asbun HJ, Ball CG, Bassi C, Beane JD, **Behrman SW**, Berger AC, Bloomston M, Callery MP, Christein JD, Dixon E, Drebin JA, Castillo CF, Fsher WE, Ven Fong Z, House MG, Hughes SJ, Kent TS, Kunstman JW, Malleo G, Miller BC, Salem RR, Soares K, Valero V, Wolfgang CL, Vollmer CM Jr. Risk-adjusted outcomes of clinically relevant pancreatic fistula following pancreatoduodenectomy: a model for performance evaluation. *Ann Surg* 2016 Aug;264(2):344-52.

54. Nagesh PK, Johnson NR, Boya VK, Chowdhury P, Othman SF, Khalilzad-Sharghi V, Hafeez BB, Ganju A, Khan S, **Behrman SW**, Zafar N, Chauhan SC, Jaggi M, Yallapu MM. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. *Colloids Surf B Biointerfaces* 2016; 144:8 – 20.
55. McMillan MT, Ecker BL, **Behrman SW**, Callery MP, Christein JD, Drebin JA, Fraker DL, Kent TS, Lee MK, Roses RE, Sprys MH, Vollmer CV Jr. Externalized stents for pancreatoduodenectomy provide value only in high-risk scenarios. *J Gastrointest Surg.* 2016 Dec;20(12):2052-2062.
56. McMillan MT, Allegrini V, Asbun HJ, Ball CG, Bassi C, Beane JD, **Behrman SW**, Berger AC, Bloomston M, Callery MP, Christein JD, Dickson E, Dixon E, Drebin JA, Fernandez-Del Castillo C, Fisher WE, Fong ZV, Haverick E, Hollis RH, House MG, Hughes SJ, Jamieson NB, Kent TS, Kowalsky SJ, Kunstman JW, Malleo G, McElhany AL, Salem RR, Soares KC, Sprys MH, Valero V 3rd, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr. Incorporation of procedure-specific risk into the ACS-NSQIP Surgical Risk Calculator improves the prediction of morbidity and mortality after pancreatoduodenectomy. *Ann Surg* 2017 May;265(5):978-86.
57. Abbott DE, Tzeng CW, McMillan MT, Callery MP, Kent TS, Christein JD, **Behrman SW**, Schauer DP, Hanseman DJ, Eckman MH, Vollmer CM. Pancreas fistula risk prediction: implications for hospital costs and payments. *HPB (Oxford).* 2017 Feb;19(2):140-6.
58. Weatherall T, Denbo J, Sharpe J, Martin M, O'Brien T, Gupta R, Groshart K, **Behrman S**, Dickson P. Well-differentiated, non-functional, non-ampullary duodenal neuroendocrine tumors: toward defining evaluation and management. *World J Surg* 2017 Mar;41(3):844-50.
59. Ganju A, Khan S, Hafeez BB, **Behrman SW**, Yallapu MM, Chauhan SC, Jaggi M. miRNA nanotherapeutics for cancer. *Drug Discov Today.* 2017 Feb;22(2):424-32.
60. Khan S, Sikander M, Ebeling MC, Ganju A, Kumari S, Yallapu MM, Hafeez BB, Ise T, Nagata S, Zafar N, **Behrman SW**, Wan JY, Ghimire HM, Sahay P, Pradhan P, Chauhan SC, Jaggi M. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. *Oncogene* 2017 Jan;36(4):491-500.
61. Setua S, Khan S, Yallapu MM, **Behrman SW**, Sikander M, Khan SS, Jaggi M, Chauhan SC. Restitution of tumor suppressor microRNA-145 using magnetic nanoformulation for pancreatic cancer therapy. *J Gastrointest Surg.* 2017 Jan;21(1):94-105.
62. Dolejs S, Zarzaur BL, Zyromski NJ, Pitt HA, Riall TS, Hall BL, **Behrman SW**. Does hyperbilirubinemia contribute to adverse patient outcomes following pancreatoduodenectomy. *J Gastrointest Surg.* 2017 Apr;21(4):647-56.
63. Chavez MT, Sharpe JP, O'Brien T, Patton KT, Portnoy DC, VanderWalde NA, Deneve JL, Shibata D, **Behrman SW**, Dickson PV. Management and outcomes following pancreaticoduodenectomy for ampullary adenocarcinoma. *Am J Surg.* 2017 Nov;214(5):856-61.
64. Ecker BL, McMillan MT, Asbun HJ, Ball CG, Bassi C, Beane JD, **Behrman SW**, Berger AC, Dickson EJ, Bloomston M, Callery MP, Christein JD, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, Haverick E, Hollis RH, House MG, Hughes SJ, Jamieson NB, Javed AA, Kent TS, Kowalsky SJ, Kunstman JW, Malleo G, Poruk KE, Salem RR, Schmidt CR, Soares K, Stauffer JA, Valero V, Velu LKP, Watkins AA,

- Wofgang CL, Zureikat AH, Vollmer CM Jr. Characterization and optimal management of high-risk pancreatic anastomoses during pancreatoduodenectomy. *Ann Surg.* 2018 Apr;267(4):608-16.
65. Van Buren G 2nd, Bloomston M, Schmidt CR, **Behrman SW**, Zyromski NJ, Ball CG, Morgan KA, Hughes SJ, Karanicolas PJ, Allendorf JD, Vollmer CM Jr, Ly Q, Brown KM, Velanovich V, Winter JM, McElhaney AL, Muscarella P 2nd, Schmidt CM, House MG, Dison E, Dillhoff ME, Trevino JG, Hallet J, Coburn NSG, Nakeeb A, Behrns KE, Sasson AR, Ceppa EP, Abdel-Misih SRZ, Riall TS, Sioberfein EJ, Ellison EC, Adams DB, Hsu C, Tran Cao HS, Mohammed S, Villafane-Ferriol N, Barakat O, Massarweh NN, Chai C, Mendez-Reyes JE, Fang A, Jo E, Mo Q, Fisher WE. A prospective randomized multicenter trial of distal pancreatectomy with and without routine intraperitoneal drainage. *Ann Surg.* 2017 Sept;266(3):421-31.
 66. Stiles ZE, **Behrman SW**, Glazer ES, Deneve JL, Dong L, Wan JY, Dickson PV. Predictors and implications of unplanned conversion during minimally invasive hepatectomy: an analysis of the ACS-NSQIP database. *HPB (Oxford).* 2017 Nov;19(11):957-65.
 67. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, **Behrman SW**, Benson AB 3rd, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Haracre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. Pancreatic adenocarcinoma, Version 2.2017, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw.* 2017 Aug;15(8):1028-61.
 68. Ecker BL, McMillan MT, Maggino L, Allegrini V, Asbun HJ, Ball CCG, Bassi C, Beane JD, **Behrman SW**, Berger AC, Bloomston M, Callery MP, Christein JD, Dickson E, Dixon, E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, Haverick E, Hollis RH, House MG, Hughes SJ, Jamieson NB, Kent TS, Kowalsky SJ, Kunstman JW, Maleo G, Salem RR, Soares KC, Valero V 3rd, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr. Pancreatogastrostomy Vs. Pancreatojejunostomy: a risk-stratified analysis of 5316 pancreatoduodenectomies. *J Gastrointest Surg.* 2018 Jan;22(1):68-76.
 69. Khan S, Zafar N, Khan SS, Setua S, **Behrman SW**, Stiles ZE, Yallapu MM, Sahay P, Ghimire H, Ise T, Nagata S, Wang L, Wan JY, Pradhan P, Jaggi M, Chauhan SC. Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. *HPB (Oxford).* 2018 Jun;20(6):563-72.
 70. Ecker BL, McMillan MT, Allegrini V, Bassi C, Beane JD, Beckman RM, **Behrman SW**, Dickson EJ, Callery MP, Christein JD, Drebin JA, Hollis RH, House MG, Jamieson NB, Javed AA, Kent TS, Kluger MD, Kowalsky SJ, Maggino L, Malleo G, Valero V 3rd, Velu LKP, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr. Risk factors and mitigation strategies for pancreatic fistula after distal pancreatectomy: analysis of 2026 resections from the international, multi-institutional distal pancreatectomy study group. *Ann Surg.* 2019 Jan;269(1):143-9.
 71. Ferguson MD, Dong L, Wan J, Deneve JL, Dickson PV, **Behrman SW**, Shibata D, Martin MG, Glazer ES. Molecular alterations associated with DNA repair in pancreatic adenocarcinoma are associated with sites of recurrence. *J Gastrointest Cancer.* 2019 Jun;50(2):285-91.
 72. Stiles ZE, **Behrman SW**, Deneve JL, Glazer ES, Dong L, Wan JY, Martin MG, Dickson PV. Ampullary adenocarcinoma: Defining predictors of survival and the impact of adjuvant therapy following surgical resection for stage I disease. *J Surg Oncol.* 2018 Jun;117(7):1500-1508.
 73. Stiles ZE, Dickson PV, Deneve JL, Glazer ES, Dong, L, Wan JY, **Behrman SW**. The impact of unplanned conversion to an open procedure during minimally invasive pancreatectomy. *J Surg Res.* 2018 Jul;227:168-77.
 74. Stiles ZE, Dickson PV, Glazer ES, Murphy AJ, Davidoff AM, **Behrman SW**, Bishop MW, Martin MG, Deneve JL. Desmoplastic small round cell tumor: A nationwide study of a rare sarcoma. *J Surg Oncol.* 2018 Jun;117:1759-67..

75. Stiles ZE, Khan S, Patton KT, Jaggi M, **Behrman SW**, Chauhan SC. Transmembrane mucin MUC13 distinguishes intraductal papillary mucinous neoplasms from non-mucinous cysts and is associated with high-risk lesions. *HPB (Oxford)*. 2018 Jan;21:87-95.
76. Lewis RH, Glazer ES, Bittenbinder DM, O'Brien T, Deneve JL, Shibata D, **Behrman SW**, Vanatta JM, Satapathy SK, Dickson PV. Outcomes following resection of hepatocellular carcinoma in the absence of cirrhosis. *J Gastrointest Cancer*. 2019 Dec;50:808-15.
77. Stiles ZE, Glazer ES, Deneve JL, Shibata D, **Behrman SW**, Dickson PV. Long-term implications of unplanned conversion during laparoscopic liver resection for hepatocellular carcinoma. *Ann Surg Onc*. 2018 Jan;26:282-89.
78. Wcislak SM, Stiles ZE, Deneve JL, Glazer ES, **Behrman SW**, Farooq FT, Dickson PV. Hypervascular lesions of the pancreas: think before you act. *Am J Surg*. 2019 Aug;218(2):362-7.
79. Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilias C, Wopin BM, Al-Hawary M, Asbun H, **Behrman SW**, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkkns WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Cataia G. Pancreatic Adenocarcinoma, Version 1.2019. *J Natl Compr Canc Netw*. 2019 Mar;17(3):202-210.
80. Khan S, Setua S, Kumari S, Dan N, Massey A, Hafeez BB, Yallapu MM, Stiles ZE, Alabkaa A, Yue J, Ganju A, **Behrman S**, Jaggi M, Chauhan SC. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. *Biomaterials*. 2019 Apr;208:83-97.
81. Ecker, BL, Vollmer CM Jr, **Behrman SW**, Allegrini V, Aversa J, Ball CG, Barrows CE, Berger AC, Cagigas, MN, Christein JD, Dixon E, Fisher WE, Freedman-Weiss M, Guzman-Pruneda F, Hollis RH, House MG, Kent TS, Kowalsky SJ, Malleo, G, Salem RR, Salvia R, Schmidt CR, Seykora TF, Zheng R, Zureikat AH, Dickson PV. Role of adjuvant multimodality therapy after curative-intent resection of ampullary carcinoma. *JAMA Surg*. 2019 Aug;154:706-14.
82. Trudeau MT, Maggino L, Ecker BL, Vollmer CM; Pancreatic Head Resection after Roux-en-Y Gastric Bypass Study Group. Pancreatic head resection following Roux-en-Y gastric bypass: operative considerations and outcomes. *J Gastrointest Surg*. 2020 Jan;24:76-87.
83. Zhou Y, Drake J, Deneve JL, **Behrman SW**, Dickson PV, Shibata D, Glazer ES. Rising BMI is associated with increased rate of clinically relevant pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. *Am Surg*. 2019 Dec;85:1376-80.
84. Tsao MW, Delozier OM, Stiles ZE, Magnotti LJ, **Behrman SW**, Deneve JL, Glazer ES, Yakoub D, Dickson PV. The impact of race and socioeconomic status on the presentation, management and outcomes for gastric cancer patients: Analysis from a metropolitan area in the southeast United States. *J Surg Oncol*. 2020 Mar;121:494-502.
85. Kumari S, Khan S, Sekhri R, Mandil H, **Behrman S**, Yallapu MM, Chauhan SC, Jaggi M. Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. *Br J Cancer*. 2020 Jan;122:121-31.
86. Drake JA, Stiles ZE, **Behrman SW**, Glazer ES, Deneve JL, Somer BG, Vanderwalde NA, Dickson PV. The utilization and impact of adjuvant therapy following neoadjuvant therapy and resection of pancreatic adenocarcinoma: does more really matter? *HPB (Oxford)*. 2020 Nov;22(11):1530-41.
87. Trudeau MT, Casciani F, Ecker BL, Maggino L, Deykora TF, Puri P, McMillan MT, Miller B, Pratt WB, Asbun HJ, Ball CG, Bassi C, **Behrman SW**, Berger AC, Bloomston MP, Callery MP, Castillo CF, Christein JD, Dillhoff ME, Dickson EJ, Dixon E, Fisher WE, House MG, Hughes SJ, Kent TS, Malleo G, Salem RR, Wolfgang CL, Zureikat AH, Vollmer CM; on the behalf of the Pancreas Fistula Study Group. The fistula risk score catalog: toward precision medicine for pancreatic fistula after pancreatoduodenectomy. *Ann Surg*. 2020 (Online ahead of print).

88. Moekotte AL, van Roessel S, Malleo G, Rajak R, Ecker BL, Fontana M, Han HS, Rabie M, Roberts KJ, Khalil, K, Whaite SA, Robinson S, Halimi A, Zarantonello L, Fusai GK, Gradinariu G, Alseidi A, Bonds M, Dreyer S, Jamieson NB, Mowbray N, Al-Sarireh B, Mavroeidis VK, Soonawalla Z, Napoli N, Boggi U, Kent TS, Fisher WE, Tang CN, Bolm L, House MG, Dillhoff ME, **Behrman SW**, Nakamura M, Ball CG, Berger AC, Christein JD, Zureikat AH, Salem RR, Vollmer CM, Salvia R, Besselink MG, Abu Hilal M: International Study Group on Ampullary Cancer (ISGACA). Development and external validation of a prediction model for survival in patients with resected ampullary adenocarcinoma. *Eur J Surg Oncol.* 2020 Sep;46(9):1717-26.
89. Trudeau MT, Casciani F, Maggino L, Seykora TF, Asbun HJ, Ball CG, Bassi C, **Behrman SW**, Berger AC, Bloomston MP, Callery MP, Castillo CF, Christein JD, Dillhoff ME, Dickson EJ, Dixon E, Fisher WE, House MG, Hughes SJ, Kent TS, Malleo G, Salem RR, Wolfgang CL, Zureikat AH, Vollmer CM; Pancreas Fistula Study Group. The influence of intraoperative blood loss on fistula development following pancreatoduodenectomy. *Ann Surg.* 2020 (online ahead of print).
90. Casciani F, Trudeau MT, Asbun HJ, Ball CG, Bassi C, **Behrman SW**, Berger AC, Bloomston MP, Callery MP, Christein JD, Falconi M, Fernandez-Del Castillo C, Dillhoff ME, Dickson EJ, Dixon E, Fisher WE, House MG, Hughes SJ, Kent TS, Malleo G, Partelli S, Salem RR, Stauffer JA, Wolfgang CL, Zureikat AH, Vollmer CM Jr; Pancreas Fistula Study Group. Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula development. *Surgery.* 2021 Apr;169(4):708-20.
91. Tempero MA, Malafa MP, Al-Hawary M, **Behrman SW**, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reygold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2021 Apr 1;19(4):439-57.
92. Delozier OM, Stiles ZE, Shibata D, Deneve JL, Monroe J, Dickson PV, Mathew A, Chandler RG, **Behrman SW**. Gracilis flap reconstruction after proctocolectomy for malignancy and inflammatory bowel disease. *Am Surg.* 2021 Apr 22 Online ahead of print.
93. Casciani F, Trudeau MT, Asbun HJ, Ball CG, Bassi C, **Behrman SW**, Berger AC, Bloomston MP, Callery MP, Christein JD, Falconi M, Fernandez-Del Castillo C, Dillhoff ME, Dickson EJ, Dixon E, Fisher WE, House MG, Hughes SJ, Kent TS, Kunstman JW, Malleo G, Partelli S, Wolfgang CL, Zureikat AH, Vollmer CM; Pancreas Fistula Study Group. The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysis. *Surgery.* 2021 Apr 27 Online ahead of print.
94. Brubaker LS, Casciani F, Fisher WE, Wood AL, Cagigas MN, Trudeau MT, Parikh VJ, Baugh KA, Asbun HJ, Ball CG, **Behrman SW**, Berger AC, Bloomston MP, Callery MP, Christein JD, Fernandez-Del Castillo C, Dillhoff ME, Dixon E, House MG, Hughes SJ, Kent TS, Kunstman JW, Wolfgang CL, Zureikat AH, Vollmer CM Jr, Van Buren G 2nd. A risk-adjusted analysis of drain use in pancreaticoduodenectomy: Some is good, but more may not be better. *Surgery.* 2021 Aug 22 Online ahead of print.

BOOKS, BOOK CHAPTERS

1. Behrman, Stephen W. (Guest Ed). Benign Pancreatic Disorders. *Surgical Clinics of North America* 87(6). Philadelphia, Elsevier, Inc. 2007.
2. Behrman, SW., Fowler, ES. Pathophysiology of chronic pancreatitis. *Benign Pancreatic Disorders, Surgical Clinics of North America*, Stephen W. Behrman, (Ed). Philadelphia, Elsevier, Inc. 2007:1309-1324.

3. Behrman, SW. Acute Pancreatitis. Acute Care Surgery and Trauma, Stephen M. Cohn, MD (Ed). London, Informa UK Ltd. 2009:382-389.
4. Behrman, Stephen W. (Co-Ed). Update in Pancreatic Disease. Surgical Clinics of North America. Philadelphia. Elsevier, Inc. 2012.
5. Dickson, VP., Behrman, SW.: Management of Pancreatic Neuroendocrine Tumors. Surg Clinics of North America. 2013 Jun;93(3):675-91.
6. Behrman, SW, Martin, RF: Modern Concepts in Pancreatic Surgery. Surg Clinics of North America. 2013. Jun;93(3)
7. Behrman, Stephen W. Acute Pancreatitis. Surgery Evidence-Based Practice. Stephen M. Cohn, MD FACS, (Ed) & Steven T. Brower, MD, FACS (Ed). People's Medical Publishing House-USA. 2012:421-428.
8. Dickson, PV, Behrman, SW.: "Distal Cholangiocarcinoma". Surg Clin North Am. 2014 Apr;94(2):325 - 342.
9. Behrman SW. Acute Pancreatitis. Acute Care Surgery and Trauma – 2nd edition. Stephen M. Cohn, MD FACS, (Ed). *In Press*
10. Stiles, ZE, Behrman, SW. Drainage Following Distal Pancreatectomy – Is it Necessary?. Hepato-Pancreato-Biliary and Transplant Surgery. Quyen D. Chu, MD; Charles M. Vollmer, MD; Gazi B. Zibari, MD; Susan L. Orloff, MD; Mallory Williams, MD; Mariano E. Gimenez, MD (Eds). Beaux Books Publishing. 2018:490-4.

Presentations at National Meetings:

- October 5-7, 1989 "Early fixation of femur fractures: an analysis based on injury severity". American Association for the Surgery of Trauma, Chicago, IL
- September 6-8, 1990 "Effect of hypertonic saline/dextran on blood flow distribution after shock". American Association for the Surgery of Trauma, Tucson, AZ
- October 7-12, 1990 "The effect of growth hormone on nutritional markers in enterally fed immobilized trauma patients" American College of Surgeons, Surgical Forum, San Francisco, CA
- January 14-17, 1998 "Breakdown of intestinal repair following laparotomy for trauma: incidence, risk factors and strategies for prevention". Eastern Association for the Surgery of Trauma, Sanibel Island, FL
- May 15-19, 1999 "Gastric outlet obstruction requiring surgical resection is infrequently associated with *Helicobacter pylori*". Society for the Surgery of the Alimentary Tract, Orlando, FL
- May 21-24, 2000 "*Helicobacter pylori* in operatively managed patients with nonvariceal acute upper gastrointestinal hemorrhage". Society for the Surgery of the Alimentary Tract, San Diego, CA
- February 4-7, 2001 "An assessment of *Helicobacter pylori* status, cocaine use and gastric acid analysis in perforated duodenal ulcer disease: implications for surgical management". Southeastern Surgical Congress, New Orleans, LA
- February 2-5, 2002 "The safety and efficacy of prosthetic hernia repair in clean-contaminated and contaminated wounds". Southeastern Surgical Congress, Nashville, TN.
- February 1-3, 2004 "A modern analysis of morbidity following pancreatic resection". Southeastern Surgical Congress, Atlanta, GA
- February 17-21, 2006 "Total pancreatectomy for chronic pancreatitis: indications, outcomes and recommendations". Southeastern Surgical Congress, Orlando, FL
- February 9-12, 2008 "Intra-abdominal sepsis following pancreatectomy: incidence, risk factors, microbiology, management and outcome". Southeastern Surgical Congress, Birmingham, AL
- March 12-15, 2009 "Microbiology of secondary and tertiary pancreatic infections: implications for anti-microbial management". American Hepato-Pancreato-Biliary Association, Miami, FL
- February 12-15, 2011 "Ligation versus Reconstruction of the Soft Pancreatic Remnant following

- Pancreaticoduodenectomy – Revisiting an Old Friend”.
Southeastern Surgical Congress, Chattanooga, TN
- May 5-10, 2011 “Routine Peritoneal Drainage Following Elective Distal Pancreatectomy—
Is it Necessary?” Digestive Disease Week, Chicago, IL
- May 6 & 7, 2011 “Toward Defining The Grade C Pancreatic Fistula Following
Pancreaticoduodenectomy: Incidence, Risk Factors, Management and
Outcome” and “Routine Peritoneal Drainage Following Elective Distal
Pancreatectomy—Is it Necessary?” Pancreas Club Meeting, Chicago, IL
- May 5-10, 2011 “Routine Peritoneal Drainage Following Elective Distal Pancreatectomy—
Is it Necessary?” Society for Surgery of the Alimentary Tract Meeting,
Chicago, IL
- March 6-10, 2012 “Should I Place a J-tube?”
America Hepato-Pancreato-Biliary Association Meeting, Miami, FL
- May 2-3, 2014 “Co-delivery of Gemcitabine and Mis-205 in Polymeric Micelles for the
Treatment of Pancreatic Carcinoma”
Pancreas Club Meeting, Chicago, IL
- May 4, 2014 “Does Routine Drainage of the Operative Bed Following Elective Distal
Pancreatectomy Reduce Complications?”
Society for Surgery of the Alimentary Tract Meeting, Chicago, IL
- July 26 – 29, 2014 “Does Routine Drainage of the Operative Bed Following Elective Distal
Pancreatectomy Reduce Complications? An Analysis of the ACS-NSQIP
Demonstration Project” and “Applying Statistical Analysis to Identify
Outliers as a Peer-Review Process Toward Quality Improvement.”
American College of Surgeons National Surgical Quality Improvement
Program, New York, NY
- September 20, 2014 “Partial vs Total Pancreatectomy for IPMN in the Young Patient” at The
Inaugural Raza A. Dilawari Multidisciplinary Cancer Symposium,
Memphis, TN
- May 20 – 24, 2016 “Restitution of Tumor Suppressor MIR-145 Using Magnetic Nanoparticles
Inhibits Pancreatic Cancer” Pancreas Club and Society for Surgery of the
Alimentary Tract, San Diego, CA
- “MUC13 Interaction With Receptor Tyrosine Kinase HER2 Drives
Pancreatic Ductal Adenocarcinoma Progression” Society for Surgery of
the Alimentary Tract, San Diego, CA
- June 1-2, 2018 “Contemporary Utilization of and Outcomes for Epidural Anesthesia
During Distal Pancreatectomy” Pancreas Club, Washington, DC

“Transmembrane Mucin MUC13 Distinguishes Intraductal Papillary Mucinous Neoplasms from Non-Mucinous cysts and is Associated with High-Risk Lesions” Pancreas Club, Washington, DC

August 2-5, 2021

“How I Dissect the Uncinate Process off the SMA and SMV” The Americas Hepato-Pancreato-Biliary Association, Miami, FL